Mallinckrodt plc (MNK)
-NYSE 44.79 
0.90(2.05%) 3:20PM EDT - Nasdaq Real Time Price
| Prev Close: | 43.89 |
|---|
| Open: | 44.00 |
|---|
| Bid: | 44.76 x 400 |
|---|
| Ask: | 44.77 x 500 |
|---|
| 1y Target Est: | 43.71 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | 43.91 - 44.86 |
|---|
| 52wk Range: | 41.00 - 48.26 |
|---|
| Volume: | 855,150 |
|---|
| Avg Vol (3m): | 1,115,460 |
|---|
| Market Cap: | 2.58B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Mallinckrodt Larger Than S&P 500 Component J.C. Penneyat Forbes(Thu, Sep 26)
- Wall Street Transcript Interview with Dr. Andrew Baum, Group Head of Health Care Research at Citigroup: Big Pharma Uses Size for Advantageous Capital-Allocation PracticesWall Street Transcript(Mon, Sep 16)
- James S.J. Manuso, the Chairman and CEO of Astex Pharmaceuticals, Inc. (ASTX), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Sep 13)
- Phase III Data from MallinckrodtZacks(Mon, Sep 9)
- Mallinckrodt Pharmaceuticals Presented 15 Posters on Investigational Drug at PAINWeek 2013Business Wire(Fri, Sep 6)
- Mallinckrodt's extended-release pain drug meets main goal of studyat Reuters(Thu, Sep 5)
- Mallinckrodt announces Phase 3 efficacy results for pain drugtheflyonthewall.com(Thu, Sep 5)
- Mallinckrodt Pharmaceuticals Announces Positive Phase 3 Efficacy Results for MNK-795, an Extended-Release Oxycodone/Acetaminophen CombinationBusiness Wire(Thu, Sep 5)
- Mallinckrodt reports human abuse liability data for MNK-795theflyonthewall.com(Wed, Sep 4)
- Mallinckrodt Pharmaceuticals Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen CombinationBusiness Wire(Wed, Sep 4)
- Mallinckrodt Pharmaceuticals to Present at Morgan Stanley Global Healthcare ConferenceBusiness Wire(Tue, Sep 3)
- Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership® at Drugfree.orgBusiness Wire(Tue, Sep 3)
- Mallinckrodt to unveil first clinical data on MNK-795theflyonthewall.com(Wed, Aug 28)
- Mallinckrodt Pharmaceuticals to Unveil First Clinical Data on MNK-795, an Extended-Release Oxycodone and Acetaminophen Combination, at PAINWeekBusiness Wire(Wed, Aug 28)
- MALLINCKRODT PLC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Aug 23)
Key Statistics
| Forward P/E (1 yr): | 18.81 |
|---|
| P/S (ttm): | 1.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | 2.81 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.85 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | 2.62 |
|---|
Business Summary
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide.
View More